Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma

Cancer Research

Volumn 69, Issue 7, 2009, Pages 2902-2911

  Nishijo, Koichi ^a   Chen, Qing Rong ^b,c   Zhang, Lei ^d   McCleish, Amanda T ^a   Rodriguez, Andrea ^a   Cho, Min Jung ^a   Prajapati, Suresh I ^a   Gelfond, Jonathan A L ^a   Chisholm, Gary B ^a   Michalek, Joel E ^a   Aronow, Bruce J ^e   Barr, Frederic G ^f   Randall, R Lor ^g   Ladanyi, Marc ^h   Qualman, Stephen J ^j   Rubin, Brian P ⁱ   LeGaIIo, Robin D ^j   Wang, Chiayeng ^d   Khan, Javed ^b   Keller, Charles ^a,k  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^k MC7784 ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR PAX3; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; ONCOPROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 FKHR FUSION PROTEIN, HUMAN; PAX3 PROTEIN, MOUSE; PAX3-FKHR FUSION PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL MOUSE; GENE MUTATION; GENE TARGETING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR CELL; ALLELE; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; PATHOLOGY; PENETRANCE; TRANSCRIPTION INITIATION;

ALLELES; ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, KNOCKOUT; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PENETRANCE; RHABDOMYOSARCOMA, ALVEOLAR; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 66149138870     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3723     Document Type: Article

References (46)

1. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999:341:342-352.
2. Stevens MC. Treatment for childhood rhabdomyosar- coma: the cost of cure. Lancet Oncol 2005;6:77-84.
3. Davis RJ, D'Cruz CM, LoveU MA, Biegel JA, Barr FG. Fusion, of PAX7 to FTCHR by the variant t(l.;1.3)(p36;ql.4) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994;54:2869-2872
4. Anderson J, Gordon T, McManus A, et al. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyo- sarcoma: a reproducible predictor of outcome? Br J Cancer 2001;85:831-835.
5. Keller C, Arenklel BR, Coffin. CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarco- mas in conditional Pax3:Fkhr mice: cooperaüvity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004; 18:2614-2626
6. Keller C, Capecchl MR. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Cancer Res 2005;65:7530-7532.
7. Keller C, Hansen. MS, Coffin CM, Capecchl MR. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 2004;18:2608-2613.
8. Wachtel M, DettUng M, Koscielniak E, et al. Gene expression, signatures Identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translo- cation fusing PAX3 to NCOAl. Cancer Res 2004:64: 5539-5545
9. Lae M, Ahn EH, Mercado GE, et al. Global gene expression, profiling of PAX-FKHR fusion-positive alve- olar and PAX-FKHR fusion-negative embryonal rhabdo- myosarcomas. J Pathol 2007;212:143-151
10. Kang PB, Kho AT, Sanoudou D, et al. Variations in. gene expression, among different types of human skeletal muscle. Muscle Nerve 2005;32:483-491
11. Bakay M, Zhao P, Chen J, Hoffman EP. A web- accessible complete transcriptome of normal human and DMD muscle. Neuromuscul Disord 2002; 12 Suppl 1: S125-41.
12. Wang HW, Trotter MW, Lagos D, et al. Kaposi sarcoma herpesvlrus-induced cellular reprogramming contributes to the lymphatic endothelial gene expres- sion, in Kaposi sarcoma. Nat Genet 2004;36:687-693.
13. Henderson SR, Guiliano D, Presneau N, et al. A molecular map of mesenchymal tumors. Genome Biol 2005;6:R76.
14. Neale G, Su X, Morton CL, et al. Molecular characterization, of the pediatric preclinical, testing panel. Clin Cancer Res 2008;14:4572-4583.
15. Walkley CR, Qudsi R, Sankaran VG, et al. Conditional mouse osteosarcoma, dependent on. p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008;22:1662-1676.
16. Mao J, Ligon KL, Rakhlin. EY, et al. A novel somatic mouse model to survey tumorigenic poten- tial applied to the Hedgehog pathway. Cancer Res 2006;66:10171-10178
17. Zhang L, Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 2006;25:2615-2627
18. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A. is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008;27:6550-6560.
19. Relaix F, Montarras D, Zaffran S, et al. Pax.3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J Cell Biol 2006;172:91-102.
20. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005:102:15545-15550.
21. Ungenau DM, Keefe MD, Storer NY, et al. Effects of RAS on. the genesis of embryonal, rhabdomyosarcoma. Genes Dev 2007:21:1382-1395.
22. Tamayo P, Scanfeld D, Ebert BL, Gillette MA, Roberts CW, Mesirov JP. Metagene projection for cross-platform, cross-species characterization of global, transcriptional, states. Proc Natl Acad Sd USA 2007;104:5959-5964
23. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification, of a PAX- FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006;66:6936-6946
24. Galindo RL, Allport JA, Olson EN. A DrosophUa model of the rhabdomyosarcoma initiator PAX7-.FKHR. Proc Natl. Acad Sei U S A 2006; 103:13439-44.
25. Zhang L, Wang C. PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kipl, a potential role for elevated Skp2 expression. J Biol Chem 2003;278:27-36.
26. Barber TD, Barber MC, Tomescu O, Barr FG, Ruben S, Friedman TB. Identification of target genes regulated by PAX3 and PAX3-FKHR in. embryogenesis and alveolar rhabdomyosarcoma. Genomics 2002;79:278-284
27. Buchberger A, Freitag D, Arnold HH. A homeo-paired domain-binding motif directs MyfS expression in progenitor cells of limb muscle. Development 2007;134: 1171-80.
28. Bondar T1 Kalmina A1 Khair L1 et al. Cul4A and DDBl associate with Skp2 to target p27Kip.l for proteolysis involving the COP9 signalosome. MoI Cell Biol 2006:26: 2531.-2539.
29. Valbuena A, Vega FM, Blanco S, Lazo PA. p53 downregulat.es its activating vaccinia-related kinase 1, forming a new autoregulatory loop. MoI. Cell Biol 2006; 26:4782-4793.
30. Johnson EF, Stewart. KD, Woods KW Giranda VI, Luo Y. Pharmacological and functional comparison of the polo-like kinase famUy: insight into inhibitor and substrate specificity. Biochemistry 2007;46:9551-9563.
31. Tyler RK, Shpiro N, Marquez R, Eyers PA. VX-680 inhibits Aurora A and Aurora B kinase activity in human ceUs. CeU Cycle 2007;6:2846-2854
32. Ebauer M, Wachtel M, Niggli FK, Schäfer BW. Comparative expression, profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 2007:104: 5959-5964.
33. Begum S, Emani N, Cheung A, Wilkins O, Der S, Hamel PA. Cell-type-spedflc regulation, of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 2005; 24:1860-1872.
34. Tomescu O, XIa SJ, Strezlecki D, et al. Inducible short- term and. stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab Invest 2004: 84:1060-1070
35. Epstein JA, Song B, Lakkis M, Wang C. Tumor- specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor a receptor. MoI Cell Biol 1.998:18:411.8-30
36. De Pitta C, Tombolan L, Albiero G, et al. Gene expression, profiling Identifies potential, relevant genes in alveolar rhabdomyosarcoma pathogenesis and dis- criminates PAX3-FKITR positive and negative tumors. Int J Cancer 2006;118:2772-2781
37. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion, oncogene. Proc Natl Acad Sei USA 1999;96:13264-13269
38. Frescas D1 Pagano M1 Deregulated proteolysis by the F-box proteins SKP2 and (J-TrCP: tipping the scales of cancer. Nat Rev 2008;8:438-49.
39. Huang H, Regan KM, Wang F1 et al. Skp2 inhibits FOXOl in tumor suppression through ubiquitin-medi- ated degradation. Proc Natl Acad Sd U S A 2005;102: .1649-1654
40. Bennicelli JL1 Fredericks WJ1 Wilson RB1 Rauscher FJ ill, Barr FG. Wild type PAX3 protein and the PAX3- FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 1995;11:119-130
41. Zhang X, Gan L, Pan. H, et al. Phosphorylation of serine 256 suppresses transactivatlon by FKHR (FOXOl) by multiple mechanisms. Direct and indirect effects on nudear/cytoplasmlc shuttling and DNA binding. J Biol Chem. 2002;277:45276-45284.
42. Kindlmann GL, Weinstein DM, Jones GM, John- son CR, Capecchi MR, Keller C. Practical vessel imaging by computed tomography in live transgenic mouse models for human tumors. MoI Imaging 2005;4: 417-24.
43. Smith MA, Morton CL, Phelps DA, et al. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG1 KOS-1022) by the pediatric predinical testing program. Pediatr Blood Cancer 2008;51:34-41.
44. Ren YX, Finckenstein FG, Abdueva DA, et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008;68:6587-6597
45. Houghton. PJ, Morton CL, Tucker C1 et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940.
46. Houghton PJ, Adamson PC, Blaney S, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 2002;8:3646-3657